Omeros Corporation's Eye-Popping Surge

Biotech Omeros Corporation   (NASDAQ: OMER  )  has been on a tear since the start of September. With momentum building from a product headed for a Food and Drug Administration review and analyst upgrades, shares are up almost 16% today and have more than doubled in the last month.

OMER Chart

OMER data by YCharts.

In the following video, from The Motley Fool's health-care show Market Checkup, analyst Max Macaluso discusses the market's enthusiasm about Omeros and the opportunities and risks investors should watch for.

Investing in biotechs
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Note: This video was recorded on Oct. 2, 2013.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2667636, ~/Articles/ArticleHandler.aspx, 4/23/2014 4:03:16 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement